Close Popup1

About Us

Blogs
  • 0
  • Comment
CymaBay Therapeutics (CBAY) Given a $15.00 Price Target at Oppenheimer
12 Jan , 2018           Shared by - piyush panday


Oppenheimer set a $15.00 value focus on CymaBay Therapeutics (NASDAQ:CBAY) in a report issued on Wednesday. The business at present has a purchase rating on the biopharmaceutical organization's stock.

CBAY has been the subject of various other research reports. Cantor Fitzgerald began scope on offers of CymaBay Therapeutics in a cover Tuesday, September nineteenth. They set an overweight rating and a $16.00 value focus for the organization. Zacks Investment Research raised offers of CymaBay Therapeutics from a pitch rating to a hold rating in a write about Monday, September eighteenth. Flute player Jaffray Companies reaffirmed a purchase rating and set a $12.00 value focus on offers of CymaBay Therapeutics in a write about Friday, October 27th. HC Wainwright reaffirmed a purchase rating and set a $12.00 value focus on offers of CymaBay Therapeutics in a provide details regarding Tuesday, November 28th. At last, Leerink Swann reaffirmed a purchase rating and set a $16.00 value focus on offers of CymaBay Therapeutics in a provide details regarding Tuesday, November 28th. Two research examiners have evaluated the stock with a hold rating and ten have issued a purchase rating to the stock. CymaBay Therapeutics has an accord rating of Buy and a normal target cost of $14.50.

Offers of CymaBay Therapeutics (NASDAQ:CBAY) exchanged up $0.28 amid exchanging on Wednesday, hitting $9.91. 400,853 offers of the stock were traded, contrasted with its normal volume of 572,659. CymaBay Therapeutics has a year low of $1.46 and a year high of $10.25. The organization has an obligation to-value proportion of 0.04, a fast proportion of 7.39 and a present proportion of 7.39. The organization has a market top of $434.69, a P/E proportion of - 9.81 and a beta of 1.82.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its quarterly income comes about on Wednesday, November eighth. The biopharmaceutical organization detailed ($0.21) profit per share for the quarter, missing the Zacks' agreement gauge of ($0.19) by ($0.02). Amid a similar period in the earlier year, the organization earned ($0.25) EPS. values examiners anticipate that CymaBay Therapeutics will post - 0.82 profit for each offer for the present year.

In related news, Director Kurt Von Emster sold 59,209 offers of the stock in an exchange that happened on Tuesday, October 31st. The offers were sold at a normal cost of $9.27, for an aggregate estimation of $548,867.43. Following the consummation of the exchange, the executive now possesses 90,000 offers of the organization's stock, esteemed at around $834,300. The deal was revealed in a lawful documenting with the SEC, which is accessible through the SEC site. Likewise, Director Carl Goldfischer sold 18,000 offers of the stock in an exchange that happened on Thursday, November second. The offers were sold at a normal cost of $8.66, for an aggregate exchange of $155,880.00. Following the finishing of the exchange, the executive now straightforwardly claims 9,000 offers of the organization's stock, esteemed at around $77,940. The divulgence for this deal can be found here. Over the most recent three months, insiders sold 304,749 offers of organization stock esteemed at $2,841,832. 15.10% of the stock is possessed by insiders.

Various expansive financial specialists have as of late changed their property of CBAY. Bank of New York Mellon Corp lifted its stake in CymaBay Therapeutics by 0.8% in the second quarter. Bank of New York Mellon Corp now possesses 17,344 offers of the biopharmaceutical organization's stock esteemed at $100,000 in the wake of obtaining an extra 140 offers amid the last quarter. Marshall Wace North America L.P. obtained another position in CymaBay Therapeutics in the second quarter esteemed at around $242,000. Vanguard Group Inc. expanded its position in CymaBay Therapeutics by 20.7% in the second quarter. Vanguard Group Inc. presently claims 991,633 offers of the biopharmaceutical organization's stock esteemed at $5,712,000 in the wake of procuring an extra 170,126 offers amid the period. Ardsley Advisory Partners expanded its position in CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now possesses 50,210 offers of the biopharmaceutical organization's stock esteemed at $290,000 in the wake of procuring an extra 20,000 offers amid the period. At long last, Omega Fund Management LLC expanded its position in CymaBay Therapeutics by 82.9% in the third quarter. Omega Fund Management LLC now possesses 551,477 offers of the biopharmaceutical organization's stock esteemed at $4,445,000 in the wake of procuring an extra 250,000 offers amid the period. 69.12% of the stock is possessed by institutional speculators and flexible investments.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-arrange biopharmaceutical organization. The Company is centered around creating treatments to treat metabolic ailments, including genuine uncommon and vagrant infections. The Company's item competitors incorporate Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is utilized to treat gout.